Food and Drug Administration
recently approved Bosulif (bosutinib) to treat chronic myelogenous leukemia
(CML), a blood and bone marrow disease that usually affects older adults. U.S.
Most people with CML have a genetic mutation, called the
chromosome. Bosulif is intended for patients with chronic, accelerated or blast
phase Philadelphia chromosome positive CML who are resistant to or who cannot
tolerate other therapies, including imatinib. Philadelphia
Other drugs recently approved by FDA to treat various forms of CML include imatinib (2001), dasatinib (2006) and nilotinib (2007).